{
  "name": "XSpray Pharma",
  "slug": "xspray-pharma",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T08:48:03Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 14.72, volym 87646",
  "mfn_status": "retrieved",
  "mfn_count": 2,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/xspray-pharma/reports",
    "count": 17,
    "nasdaq_count": 17,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q2",
        "period_label": "2026 Q2",
        "date": "2026-08-05",
        "title": "Kvartalsrapport Q2 2026",
        "original_title": "Xspray Pharma delårsrapport andra kvartalet 2026",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bb97dea85ddf5e0ff88f534513012a6ab&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
            "title": "Kvartalsrapport Q2 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a5fb4d9921ffc8f338e9eaa7b76e42b81",
            "date": "2026-08-05",
            "period": "2026-q2",
            "form_type": "interim-report",
            "report_key": "2026:q2",
            "filename": "Xspray_Pharma_delarsrapport_Q2_2026.pdf",
            "text_chars": 47343,
            "sha256": "02f3f4381a8341b276240e25960e35d4230f48dc2aae298f92712946fc4ef5a6",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
                "chars": 47343
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-04-28",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Delårsrapport första kvartalet 2026",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b6b31ffd7db671f2853e808cbe9a72b56&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/afbf18fcb4e6880f16937b1dc4ce42b76",
            "date": "2026-04-28",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "20260428_Xspray_Pharma_Q1_2026_SWE.pdf",
            "text_chars": 40730,
            "sha256": "6354e9b871d541856b0eba87fe93ab69eebd9278f587c7992d5501d2c03976fb",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 40730
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-03-26",
        "title": "Årsredovisning 2025",
        "original_title": "Xspray Pharma publicerar Årsredovisning 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bbbb21defe00d4e64bb9bb66ddaf18d7d&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae01aee44e2723ff4457afdfae84de95c",
            "date": "2026-03-26",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "20260326_Xspray_Pharma_Arsredovisning_2025_Sv.pdf",
            "text_chars": 266519,
            "sha256": "2f45693c0c8e592933453650e9e5f992a05d12a66cc8101993adab71c53e431e",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 173042
              },
              {
                "number": 2,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 93475
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-12",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Delårsrapport fjärde kvartalet 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b210eed9d93a4d30bfee43bb21d2dfa36&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a2085b761e4cf1e849faa1eb4bbbeaa26",
            "date": "2026-02-12",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "20260212_Xspray_Pharma_Q4_2025_SWE.pdf",
            "text_chars": 42171,
            "sha256": "2d4e02ef3a6c68654bd187d34c08d60d376f55836f554aae4d8fd660856b7645",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 42171
              }
            ]
          }
        ],
        "alternatives": [
          {
            "source": "MFN fallback",
            "language": "sv",
            "title": "Delårsrapport fjärde kvartalet 2025",
            "release_url": "https://mfn.se/a/xspray-pharma/delarsrapport-fjarde-kvartalet-2025"
          }
        ]
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-11-05",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Delårsrapport tredje kvartalet 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7f3d8999af9843718ca8f465017f4459&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a2973552cc28b15c2dfd57999d37e8ebe",
            "date": "2025-11-05",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "20251105_Xspray_Q3_2025_SWE.pdf",
            "text_chars": 49592,
            "sha256": "8e1bca1d6c9eca51bf5afc23f5f4699d6aebafa0fde8c9ff5a2674ae28d8cd02",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 49592
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-15",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Delårsrapport andra kvartalet 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b0d221895a433d699d9e51fac6f6ec0ad&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a00d7f6790743fd3f21c1481d099647e3",
            "date": "2025-08-15",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "20250815_Q2_2025_Xspray_Pharma_Sv.pdf",
            "text_chars": 44959,
            "sha256": "22ade9dbe1298fd5338335e2aa5165d910c5593b240977b15393bf153ae7bc49",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 44959
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-07",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Delårsrapport första kvartalet 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b84be54ffb099e395070137f85e4f50fd&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae59b311919077480cf5001cb869af7bb",
            "date": "2025-05-07",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "20250507_Xspray_Pharma_Q1_2025_SWE.pdf",
            "text_chars": 37760,
            "sha256": "e039b8905a6bcd363ac7fccae066eb64a978314a6a7a04845265de116a2e6093",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 37760
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-03-27",
        "title": "Årsredovisning 2024",
        "original_title": "Xspray Pharma publicerar årsredovisning för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b90ee4f2d0d123f6356c6cbf26c0e28d8&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad983d0ddc1684674f58fc36133dc6082",
            "date": "2025-03-27",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "20250327_Xspray_Arsredovisning_2024_Sv.pdf",
            "text_chars": 248500,
            "sha256": "706f93b3b3ba44a8ef5dd4c2ba85689608b03cf91c8b2f742cad483acedb41d3",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 179367
              },
              {
                "number": 2,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 69131
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-12",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Delårsrapport fjärde kvartalet 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bbe94d8780b1a190c213beec15aad7e2e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac0d2e0c82f48999bc87eaef7f68bc17f",
            "date": "2025-02-12",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "20250212_Xspray_Pharma_Q4_2024_SWE.pdf",
            "text_chars": 42996,
            "sha256": "ce72ee6a9107d2a9d2c5632fcd774ec9a32049f529807ef35e7cb0df90ef5858",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 42996
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-11-06",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Delårsrapport tredje kvartalet 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bbe17d0868d4a7dd5c97b7cea4ed2b6d0&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a95f135cd65eb2de4cd562a7765280325",
            "date": "2024-11-06",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "20241106_Xspray_Q3_2024_SWE.pdf",
            "text_chars": 52179,
            "sha256": "999635d16ff274d2a309dfbbb1c11fd1df287aa8e5acbe8a8eb820e96aa4f6be",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 52179
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-07",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Delårsrapport andra kvartalet 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bee040ef17a0ba896880fbca03f7fab90&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad0827b50527699a23f334ff8952dd66d",
            "date": "2024-08-07",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "20240807_Xspray_Q2_2024_SWE.pdf",
            "text_chars": 44933,
            "sha256": "a6a3cf1b14ed8c151100b86619225f73bc2624eb47761beb82eb8c10bd3e764c",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 44933
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-08",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Delårsrapport första kvartalet 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bf6047f3a3d8dda0ea3f215bbc18f12c6&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae427f3bc7ac305abb40e57c5e2b0d750",
            "date": "2024-05-08",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.pdf",
            "text_chars": 40316,
            "sha256": "17e047cbc2fa02bba9510944f39e37cb24867cbfeb9a05888688fc7818f606fb",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 40316
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-03-27",
        "title": "Årsredovisning 2023",
        "original_title": "Xspray Pharma publicerar årsredovisning 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba29714bc618f03e7f4c72f0ac1adc1bf&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad9fd8db8f5736fc5fabd195c1072b922",
            "date": "2024-03-27",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "20240327_Xspray_Pharma_Arsredovisning_2023_Sv.pdf",
            "text_chars": 247137,
            "sha256": "57da7d7a02646ea2eefe2f61c826a6b3e6635b9ba76fc6c95a33291ce513d650",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 179074
              },
              {
                "number": 2,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 68061
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-14",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "Delårsrapport fjärde kvartalet 2023",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd16eef133f40bb919111be18d697058d&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a140a716efe18f1eb185d46b153d16935",
            "date": "2024-02-14",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "2024_02_14_XsprayPharma_Q4_Rapport_SWE.pdf",
            "text_chars": 45285,
            "sha256": "ee901f87fdb52b52194f01ea087543f9f618c13c5bb010140dcb8d328b0d60b3",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 45285
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-11-08",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "Delårsrapport tredje kvartalet 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b0e99301c43a160e104a2d8e31cc05d7a&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a92ea5449e715c9e54884b6eb64ddabd4",
            "date": "2023-11-08",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.pdf",
            "text_chars": 48050,
            "sha256": "f61c4d7618408aa09df8cd67ed266e4d4648ce31270bddc9fda8960fe66d43e7",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 48050
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-02",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "Delårsrapport andra kvartalet 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b65b2da9c0cea0909d3fcf2e0af50fd5c&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae3558d64f63ccbf7c7ada0c7ccbf2557",
            "date": "2023-08-02",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "Xspray_Q2_Rapport_SWE.pdf",
            "text_chars": 43237,
            "sha256": "46f070043e9ca848d42fa0b69b0b0ce8d442f436ec7f568c31599d110c2237d7",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 43237
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-05-04",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "Delårsrapport första kvartalet 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b915d08ed3d340c5c2238ff2e30b5184c&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/abca29c48cc1571e3bd7eaf6682e27ba1",
            "date": "2023-05-04",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "20230504_Xspray_Pharma_Q1_2023_SWE.pdf",
            "text_chars": 41483,
            "sha256": "5233c3df9bbc521cb373ca446c0c759309e5d7b037b0a536b78cbfd48ca49c6f",
            "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 41483
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 17,
  "nasdaq_report_count": 17,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "XSpray Pharma",
    "identity": {
      "issuer": "XSpray Pharma AB (publ)",
      "lei": "549300NGRQCNZ3X4L157",
      "source": "FI insynsregister",
      "row_count": 49,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "XSpray Pharma",
      "query": "XSpray Pharma AB (publ)",
      "candidate_count": 346
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T08:48:02Z",
    "insider": {
      "transactions": 49,
      "all_export_rows": 49,
      "acquisitions": 13,
      "disposals": 8,
      "other": 28,
      "acquisition_value_sek": 8854879.37,
      "disposal_value_sek": 1395041.37,
      "characters": {
        "Avyttring": 8,
        "Förvärv": 13,
        "Lösen minskning": 4,
        "Teckning": 22,
        "Tilldelning": 2
      }
    },
    "short_selling": {
      "aggregate_percent": 1.08,
      "current_public_positions": 0,
      "historical_changes": 0,
      "current_position_sum_over_0_5": 0
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX2489842",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/xspray?id=TX2489842"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Xspray Pharma AB",
      "expected_name": "XSpray Pharma",
      "match_score": 100.0,
      "slug": "xspray-pharma",
      "url": "https://mfn.se/all/a/xspray-pharma",
      "metadata": {
        "country": "Sverige",
        "list": "Small Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://career.modularfinance.se"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX2489842",
      "asset_class": "SHARES",
      "isin": "SE0009973563",
      "symbol": "XSPRAY",
      "company": "Xspray Pharma",
      "market": null,
      "last_sale_price": "SEK 14.98",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "XSpray Pharma AB (publ)",
      "lei": "549300NGRQCNZ3X4L157",
      "source": "FI insynsregister",
      "row_count": 49,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "XSpray Pharma",
      "query": "XSpray Pharma AB (publ)",
      "candidate_count": 346
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
      "title": "Kvartalsrapport Q2 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a5fb4d9921ffc8f338e9eaa7b76e42b81",
      "date": "2026-08-05",
      "period": "2026-q2",
      "form_type": "interim-report",
      "report_key": "2026:q2",
      "filename": "Xspray_Pharma_delarsrapport_Q2_2026.pdf",
      "text_chars": 47343,
      "sha256": "02f3f4381a8341b276240e25960e35d4230f48dc2aae298f92712946fc4ef5a6",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
          "chars": 47343
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/afbf18fcb4e6880f16937b1dc4ce42b76",
      "date": "2026-04-28",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "20260428_Xspray_Pharma_Q1_2026_SWE.pdf",
      "text_chars": 40730,
      "sha256": "6354e9b871d541856b0eba87fe93ab69eebd9278f587c7992d5501d2c03976fb",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 40730
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae01aee44e2723ff4457afdfae84de95c",
      "date": "2026-03-26",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "20260326_Xspray_Pharma_Arsredovisning_2025_Sv.pdf",
      "text_chars": 266519,
      "sha256": "2f45693c0c8e592933453650e9e5f992a05d12a66cc8101993adab71c53e431e",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 173042
        },
        {
          "number": 2,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 93475
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a2085b761e4cf1e849faa1eb4bbbeaa26",
      "date": "2026-02-12",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "20260212_Xspray_Pharma_Q4_2025_SWE.pdf",
      "text_chars": 42171,
      "sha256": "2d4e02ef3a6c68654bd187d34c08d60d376f55836f554aae4d8fd660856b7645",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 42171
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a2973552cc28b15c2dfd57999d37e8ebe",
      "date": "2025-11-05",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "20251105_Xspray_Q3_2025_SWE.pdf",
      "text_chars": 49592,
      "sha256": "8e1bca1d6c9eca51bf5afc23f5f4699d6aebafa0fde8c9ff5a2674ae28d8cd02",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 49592
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a00d7f6790743fd3f21c1481d099647e3",
      "date": "2025-08-15",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "20250815_Q2_2025_Xspray_Pharma_Sv.pdf",
      "text_chars": 44959,
      "sha256": "22ade9dbe1298fd5338335e2aa5165d910c5593b240977b15393bf153ae7bc49",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 44959
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae59b311919077480cf5001cb869af7bb",
      "date": "2025-05-07",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "20250507_Xspray_Pharma_Q1_2025_SWE.pdf",
      "text_chars": 37760,
      "sha256": "e039b8905a6bcd363ac7fccae066eb64a978314a6a7a04845265de116a2e6093",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 37760
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad983d0ddc1684674f58fc36133dc6082",
      "date": "2025-03-27",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "20250327_Xspray_Arsredovisning_2024_Sv.pdf",
      "text_chars": 248500,
      "sha256": "706f93b3b3ba44a8ef5dd4c2ba85689608b03cf91c8b2f742cad483acedb41d3",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 179367
        },
        {
          "number": 2,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 69131
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac0d2e0c82f48999bc87eaef7f68bc17f",
      "date": "2025-02-12",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "20250212_Xspray_Pharma_Q4_2024_SWE.pdf",
      "text_chars": 42996,
      "sha256": "ce72ee6a9107d2a9d2c5632fcd774ec9a32049f529807ef35e7cb0df90ef5858",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 42996
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a95f135cd65eb2de4cd562a7765280325",
      "date": "2024-11-06",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "20241106_Xspray_Q3_2024_SWE.pdf",
      "text_chars": 52179,
      "sha256": "999635d16ff274d2a309dfbbb1c11fd1df287aa8e5acbe8a8eb820e96aa4f6be",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 52179
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad0827b50527699a23f334ff8952dd66d",
      "date": "2024-08-07",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "20240807_Xspray_Q2_2024_SWE.pdf",
      "text_chars": 44933,
      "sha256": "a6a3cf1b14ed8c151100b86619225f73bc2624eb47761beb82eb8c10bd3e764c",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 44933
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae427f3bc7ac305abb40e57c5e2b0d750",
      "date": "2024-05-08",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.pdf",
      "text_chars": 40316,
      "sha256": "17e047cbc2fa02bba9510944f39e37cb24867cbfeb9a05888688fc7818f606fb",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 40316
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad9fd8db8f5736fc5fabd195c1072b922",
      "date": "2024-03-27",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "20240327_Xspray_Pharma_Arsredovisning_2023_Sv.pdf",
      "text_chars": 247137,
      "sha256": "57da7d7a02646ea2eefe2f61c826a6b3e6635b9ba76fc6c95a33291ce513d650",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 179074
        },
        {
          "number": 2,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 68061
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a140a716efe18f1eb185d46b153d16935",
      "date": "2024-02-14",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "2024_02_14_XsprayPharma_Q4_Rapport_SWE.pdf",
      "text_chars": 45285,
      "sha256": "ee901f87fdb52b52194f01ea087543f9f618c13c5bb010140dcb8d328b0d60b3",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 45285
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a92ea5449e715c9e54884b6eb64ddabd4",
      "date": "2023-11-08",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.pdf",
      "text_chars": 48050,
      "sha256": "f61c4d7618408aa09df8cd67ed266e4d4648ce31270bddc9fda8960fe66d43e7",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 48050
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae3558d64f63ccbf7c7ada0c7ccbf2557",
      "date": "2023-08-02",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "Xspray_Q2_Rapport_SWE.pdf",
      "text_chars": 43237,
      "sha256": "46f070043e9ca848d42fa0b69b0b0ce8d442f436ec7f568c31599d110c2237d7",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 43237
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/abca29c48cc1571e3bd7eaf6682e27ba1",
      "date": "2023-05-04",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "20230504_Xspray_Pharma_Q1_2023_SWE.pdf",
      "text_chars": 41483,
      "sha256": "5233c3df9bbc521cb373ca446c0c759309e5d7b037b0a536b78cbfd48ca49c6f",
      "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 41483
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/xspray-pharma",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 12882,
      "sha256": "27214fc8323352244a118540568531cf7f29be4ec9075f86f33df4602aab8388",
      "url": "/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 12882
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/xspray-pharma/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/xspray-pharma/market/history.json",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/xspray-pharma/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/xspray-pharma/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/xspray-pharma/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/xspray-pharma/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/xspray-pharma/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/xspray-pharma/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/xspray-pharma/finansinspektionen",
    "transaction_count": 49,
    "aggregate_short_percent": 1.08,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/xspray-pharma/llms.txt",
  "json_url": "/company/xspray-pharma/company.json",
  "document_index_url": "/company/xspray-pharma/documents.json",
  "absolute_url": "https://spela.port0.org/company/xspray-pharma"
}